AstraZeneca’s R&D Site in Mölndal, Sweden. Credit: Erik031.

AstraZeneca has secured the US Food and Drug Administration (FDA) priority review for Farxiga (dapagliflozin) to treat heart failure with reduced ejection fraction (HFrEF).

The US regulator accepted a supplemental New Drug Application (sNDA) granting priority review for Farxiga that seeks to reduce the risk of cardiovascular (CV) death and heart failures (HF) in adults with and without type-2 diabetes (T2D).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The sNDA comes from results of the Phase III DAPA-HF trial published in September last year in The New England Journal of Medicine.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “Farxiga is well established in the treatment of type-2 diabetes and this Priority Review shows its potential to also impact millions of patients with heart failure.

“If approved, Farxiga will be the first and only medicine of its kind indicated to treat patients with heart failure.”

Farxiga is an oral once-daily selective sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as monotherapy or in combination to improve glycaemic control. The drug also supports weight loss and lowers blood pressure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Farxiga completed more than 35 clinical trials, excluding ongoing Phase IIb / III trials, with testing on more than 35,000 patients overall.

In August last year, FDA granted Fast Track designation for Farxiga development to delay renal failure progression, prevent CV and renal death in patients suffering from chronic kidney disease.

A month later, the regulator awarded another Fast Track designation for the development of Farxiga in HF.

Notably, AstraZeneca divested Arimidex and Casodex rights recently to French pharmaceutical company Juvisé Pharmaceuticals for $181m.